
Opinion|Videos|March 11, 2025
Optimizing Treatment Sequencing in Advanced Colorectal Cancer
Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)?
- What further research is needed to understand optimal sequencing of these therapies better?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
Clinician Shortages, Access Gaps Challenge Rural Primary Care
3
Diet, Lifestyle Come Into Focus for Managing Multiple Sclerosis: Rebecca Spain, MD
4
FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome
5













































